{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-124907","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.492234+00:00","generated_at":"2026-06-21T08:46:16.196368+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023","bullets":["CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).","RAPID Phase 3 data: 64% conversion at 30 min (etripamil) vs 31% placebo; median time 17 min vs 54 min.","NDA submission for etripamil in PSVT expected mid-2023; development in AFib-RVR also underway.","Initial target market 600,000–900,000 patients; net price estimate $500–$1,000/Rx; cardiologists report 53% adoption."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-124907","json":"https://secwatch.observer/filing/0001104659-22-124907.json","markdown":"https://secwatch.observer/filing/0001104659-22-124907.md","text":"https://secwatch.observer/filing/0001104659-22-124907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/tm2232091d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:46:16.196368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80ae252d43","claim":"Francis Plat departed as Chief Scientific Officer at Milestone Pharmaceuticals Inc..","evidence_excerpt":"Mr. Oliveto, the Company’s Chief Executive Officer, announced Mr. Francis Plat’s intention to retire as Chief Scientific Officer from the Company, effective December 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}